A West Perth company developing artificial intelligence to diagnose heart disease has raised $15 million to pursue the United States market.
Vous n'êtes pas connecté
ASX-listed Artrya, which is commercialising coronary disease diagnosis support products, has announced a successful $15 million raise through a share placement. In a statement on Friday, the company said it had received binding commitments under a two-tranche placement at $0.73 per share. The proceeds will be used to progress regulatory applications for its Salix Coronary… The post Artrya raises $15 million appeared first on Australian Manufacturing Forum.
A West Perth company developing artificial intelligence to diagnose heart disease has raised $15 million to pursue the United States market.
The ASX 200 Health Care Index rose in January but Morgans healthcare analyst Iain Wilkie notes February faces volatility with ...
Clinical stage biotechnology company Vaxxas, which is commercialising a needle-free vaccine delivery platform, has added three new expert advisors to...
Firetail Resources has secured commitments to raise $3 million to fund a high-impact exploration program at the Skyline project. ...
The Endeavor silver-zinc mine. Image: PolymetalsPolymetals is celebrating the confirmation of a $35 million single-tranche placement as it works to...
Calix/PLS demo plant construction resumes Calix announced the recommencement of the Mid-Stream Demonstration Plant Project developed in a Joint...
THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES FOR DISSEMINATION IN THE UNITED STATES TORONTO — Silver Storm Mining Ltd....
Strata Minerals has received firm commitments to raise $1.6m at $0.03 per share to kick off a maiden RC drilling ...
Maritime Launch (CBOE:MAXQ) has secured agreements and regulatory approval to complete its C$1.6 million financing at $0.05 a share.